Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

rituximab conjugate CON-4619

A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:aurixim antibody conjugate
US brand name:Aurixim
Code name:CON-4619
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search